Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions DOI Creative Commons

Elisa Balboa,

Faride Saud,

Claudia Parra-Ruiz

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: June 24, 2024

The global prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is increasing, now affecting 25%–30% the population worldwide. MASLD, characterized by hepatic steatosis, results from an imbalance in lipid metabolism, leading to oxidative stress, lipoperoxidation, and inflammation. activation autophagy, particularly lipophagy, alleviates steatosis regulating intracellular levels. Lutein, a carotenoid with antioxidant anti-inflammatory properties, protects against liver damage, individuals who consume high amounts lutein have lower risk developing MASLD. Evidence suggests that could modulate autophagy-related signaling pathways, such as transcription factor EB (TFEB). TFEB plays crucial role homeostasis linking autophagy energy metabolism at transcriptional level, making potential target STARD3, transmembrane protein binds transports cholesterol sphingosine lysosomes endoplasmic reticulum mitochondria, has been shown transport bind affinity. This may play uptake liver, contributing decrease regulation stress review summarizes current knowledge on pathways it involved in, its relationship pharmacological strategy treat steatosis.

Language: Английский

The Pivotal Role of the Membrane-Bound O-Acyltransferase Domain Containing 7 in Non-Alcoholic Fatty Liver Disease DOI Creative Commons
Preethi Chandrasekaran, Ralf Weiskirchen

Livers, Journal Year: 2023, Volume and Issue: 4(1), P. 1 - 14

Published: Dec. 20, 2023

Non-alcoholic fatty liver disease (NAFLD) is a common and prevalent disorder affecting 25 percent of the adults in United States 32 globally. It one causes chronic characterized by steatosis, which can lead to inflammation, fibrosis, cirrhosis. NAFLD strongly associated with obesity insulin resistance. Multiple genetic variants have been consistently found be NAFLD; them TMC4-MBOAT7 loci. One variant (rs641738 C>T) within MBOAT7 encoding lysophosphatidyl inositol acyltransferase increases risk for development triggers hepatic inflammation regulating arachidonic acid levels. This review provides an overview gene, pathogenesis NAFLD, understanding regulation mechanistic link between NAFLD. further summarizes pathophysiologically relevant vivo vitro studies on challenges treating complex recent progress made treatment As such, this useful information interrelation, has potential deciphering novel therapeutic targets rather than well-known such as PNPLA3 TM6SF2.

Language: Английский

Citations

4
Metabolic dysfunction associated steatotic liver disease in resource-limited settings DOI
Mark Sonderup, Luis Antonio Díaz, Juan Pablo Arab

et al.

Elsevier eBooks, Journal Year: 2024, Volume and Issue: unknown, P. 167 - 175

Published: Feb. 15, 2024

Language: Английский

Citations

1
Trends of nonalcoholic fatty liver research in Southeast Asia from 2004 to 2022: A bibliometric analysis DOI

Vivien Joyce D. Josol,

Paul Benedic U. Salvador, Linnaeus Louisse A. Cruz

et al.

Obesity Medicine, Journal Year: 2023, Volume and Issue: 45, P. 100527 - 100527

Published: Nov. 28, 2023

Language: Английский

Citations

2
Evaluación comparativa de APRI, FIB-4, HFS y NFS: herramientas de puntuación para la fibrosis hepática en la población mexicana con MASLD DOI Creative Commons
Bryan Adrián Priego-Parra, Arturo Triana‐Romero,

Raúl Bernal-Reyes

et al.

Revista de Gastroenterología de México, Journal Year: 2024, Volume and Issue: 89(4), P. 498 - 505

Published: May 9, 2024

La fibrosis hepática es una complicación de la enfermedad esteatótica asociada a disfunción metabólica (MASLD). Dadas las limitaciones y los riesgos biopsia hepática, necesario explorar sistemas puntuación no invasivos asequibles para población. Nuestro objetivo fue evaluar comparar el rendimiento diagnóstico puntajes APRI, FIB-4, NAFLD score Hepamet detección en individuos mexicanos con MASLD. Estudio retrospectivo muestra sujetos se estimó mediante elastografía transitoria. Se evaluaron variables sociodemográficas, epidemiológicas bioquímicas. calcularon compararon puntuaciones: índice fibrosis-4 (FIB-4), relación AST plaquetas (APRI), (HFS) (NFS). generaron curvas ROC determinaron puntos corte óptimos usando Youden. calculó sensibilidad, especificidad, valores predictivos positivos negativos razones verosimilitud. incluyeron 194 (63% mujeres), 150 (77.3%) fueron clasificados como MASLD 44 (22.7%) controles sin hepática. prevalencia avanzada del 15.3%. Los 0.57 1.85 0.08 HFS −0.058 NFS demostraron rendimientos diagnósticos áreas bajo 0.79, 0.80, 0.70 0.68, respectivamente. son útiles evaluación MASLD, siendo FIB-4 APRI mejor diagnóstico. Liver is complication of metabolic dysfunction-associated steatotic liver disease Given the limitations and risks biopsy, examining noninvasive scoring systems that are affordable for population necessary. Our aim was to evaluate compare diagnostic yield score, instruments detecting in Mexican subjects with A retrospective study conducted on sample calculated through transient elastography. Sociodemographic, epidemiologic, biochemical were evaluated. Scores utilizing (FIB-4) index, aspartate aminotransaminase-to-platelet ratio index (HFS), (NFS), then compared. curves constructed, optimum cutoff points determined Youden index. Sensitivity, specificity, positive predictive value, negative likelihood calculated. The included women), whom classified as controls disease. There 15.3% prevalence advanced fibrosis. HFS, showed yields areas under 0.70, respectively. NFS, scores useful evaluating Better found scores.

Citations

0
Exploring the lutein therapeutic potential in steatotic liver disease: mechanistic insights and future directions DOI Creative Commons

Elisa Balboa,

Faride Saud,

Claudia Parra-Ruiz

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: June 24, 2024

The global prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is increasing, now affecting 25%–30% the population worldwide. MASLD, characterized by hepatic steatosis, results from an imbalance in lipid metabolism, leading to oxidative stress, lipoperoxidation, and inflammation. activation autophagy, particularly lipophagy, alleviates steatosis regulating intracellular levels. Lutein, a carotenoid with antioxidant anti-inflammatory properties, protects against liver damage, individuals who consume high amounts lutein have lower risk developing MASLD. Evidence suggests that could modulate autophagy-related signaling pathways, such as transcription factor EB (TFEB). TFEB plays crucial role homeostasis linking autophagy energy metabolism at transcriptional level, making potential target STARD3, transmembrane protein binds transports cholesterol sphingosine lysosomes endoplasmic reticulum mitochondria, has been shown transport bind affinity. This may play uptake liver, contributing decrease regulation stress review summarizes current knowledge on pathways it involved in, its relationship pharmacological strategy treat steatosis.

Language: Английский

Citations

0